Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel). 2016;1:241–57.

Article  PubMed  Google Scholar 

Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544–57.

Article  PubMed  Google Scholar 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

Article  PubMed  Google Scholar 

Dimopoulos MA, Mikhael J, Terpos E, Leleu X, Moreau P, Blade J, et al. An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Ther Adv Hematol. 2022;13:20406207221088458.

Article  PubMed  PubMed Central  Google Scholar 

Fotiou D, Dimopoulos MA, Kastritis E. Managing renal complications in multiple myeloma. Expert Rev Hematol. 2016;9:839–50.

Article  PubMed  Google Scholar 

Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma. 2021;62:1386–95.

Article  PubMed  Google Scholar 

Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transplant. 2021;36:482–90.

Article  PubMed  Google Scholar 

Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93.

Article  PubMed  Google Scholar 

Ramasamy K, Iqbal G, Drayson MT, Brouwer R, Varghese S, Schey S, et al. Quality of life data from a prospective randomised trial of newly diagnosed myeloma patients with renal failure: optimal trial. Blood. 2020;136:5–6.

Article  Google Scholar 

Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27.

Article  PubMed  Google Scholar 

Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17:575–83. e2

Article  PubMed  Google Scholar 

Revlimid (lenalidomide) [package insert]. Princeton, NJ: Celgene Corporation, a Bristol Myers Squibb company; Revised 2023.

Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 2018;8:86.

Article  PubMed  PubMed Central  Google Scholar 

Antlanger M, Dust T, Reiter T, Bohm A, Lamm WW, Gornicec M, et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018;18:1008.

Article  PubMed  PubMed Central  Google Scholar 

Rifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, et al. Connect MM registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leuk. 2015;15:368–76.

Article  PubMed  Google Scholar 

Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016). Clin Lymphoma Myeloma Leuk. 2018;18:480–5.

Article  PubMed  Google Scholar 

Jagannath S, Abonour R, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018;2:1608–15.

Article  PubMed  PubMed Central  Google Scholar 

Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol. 2018;97:2425–36.

Article  PubMed  PubMed Central  Google Scholar 

Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, et al. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. Br J Haematol. 2021;193:93–100.

Article  PubMed  Google Scholar 

Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry. Blood Cancer J. 2021;11:134.

Article  PubMed  PubMed Central  Google Scholar 

Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer. 2022;22:901.

Article  PubMed  PubMed Central  Google Scholar 

Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  PubMed  PubMed Central  Google Scholar 

Chari A, Parikh K, Ni Q, Abouzaid S. Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide- and/or bortezomib-containing regimens without stem cell transplant in a real-world setting. Clin Lymphoma Myeloma Leuk. 2019;19:645–55.

Article  PubMed  Google Scholar 

Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005;103:1195–200.

Article  PubMed  Google Scholar 

Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.

Article  PubMed  Google Scholar 

Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22.

Article  Google Scholar 

Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–30.

Article  PubMed  Google Scholar 

Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10:17.

Article  PubMed  PubMed Central  Google Scholar 

Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97:S3–s25.

Article  PubMed  Google Scholar 

Gozzetti A, Bocchia M. Steps towards a Multiple Myeloma Cure? J Pers Med. 2022;12:1451.

Article  PubMed  PubMed Central  Google Scholar 

Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

Article  PubMed  Google Scholar 

Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195–200.

Article  PubMed  Google Scholar 

Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving cancer care for patients with CKD: the need for changes in clinical trials. Kidney Int Rep. 2022;7:1939–50.

Article  PubMed  PubMed Central  Google Scholar 

Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–75.

Article  PubMed